Comparing Oncobiologics (NASDAQ:OTLK) & Arcturus Therapeutics (NASDAQ:ARCT)

Oncobiologics (NASDAQ:OTLK) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Oncobiologics and Arcturus Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35 million	93.65	-$62.42 million	($0.77)	-0.67
Arcturus Therapeutics	$82.03 million	3.41	-$65.78 million	($3.31)	-2.97

Oncobiologics has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Oncobiologics and Arcturus Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1	2	2	0	2.20
Arcturus Therapeutics	1	1	6	2	2.90

Oncobiologics currently has a consensus price target of $5.20, indicating a potential upside of 901.35%. Arcturus Therapeutics has a consensus price target of $22.29, indicating a potential upside of 126.48%. Given Oncobiologics’ higher possible upside, research analysts plainly believe Oncobiologics is more favorable than Arcturus Therapeutics.

Volatility & Risk

Oncobiologics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.48, suggesting that its stock price is 148% more volatile than the S&P 500.

Profitability

This table compares Oncobiologics and Arcturus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%

Summary

Arcturus Therapeutics beats Oncobiologics on 8 of the 15 factors compared between the two stocks.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.